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ABSTRACT
This thesis investigates the use of a task-based Monte Carlo simulation model to forecast
headcount and manufacturing capacity requirements for a drug development organization. A
pharmaceutical drug development group is responsible for designing the manufacturing process
for new potential drug products, testing the product quality, and supplying product for clinical
trials. The drug development process is complex and uncertain. The speed to market is critical
to a company's success. Therefore, it is important to have an adequate number of employees and
available manufacturing capacity to support timely and efficient drug development. The
employees and manufacturing capacity can either be supplied internally or externally, through
contract manufacturing organizations.
This thesis formulates and empirically evaluates a simulation model designed using the Novartis
Biologics drug development process and is adaptable to other pharmaceutical organization. The
model demonstrates 7% accuracy when compared with historical data, and estimates within 13%
of the currently accepted manufacturing capacity forecasting tool. Additionally, three case
studies are included to demonstrate how the model can be used to evaluate strategic decisions.
The case studies include: a drug development process improvement evaluation, an outsourcing
evaluation, and an "at risk" development evaluation.
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CHAPTER 1 - Introduction and Overview
1.1 Problem Statement
The drug development process is complex and with many uncertainties that complicate
forecasting headcount and plant capacity requirements. The ability to forecast resources is
important because speed to market is critical and delays are costly. Business decisions involving
plant expansions and headcount expansions require foresight because the actual decision making
occurs years before benefits are fully realized. New employees can take up to a year to recruit,
hire and fully train, and new manufacturing capacity can take three to five years to build and
validate. With the slow moving, complex, and uncertain drug development process, it is very
challenging to estimate resource needs into the future.
1.2 Hypothesis
Employee and plant capacity requirements for the complex and variable drug development
process can be generalized, modeled, and presented in ways useful for long term strategic
decision making.
1.3 Thesis Goals
The goal of this thesis is three fold:
" Simulate the drug development process in a flexible and scalable model
* Evaluate the reliability and accuracy of the model
e Demonstrate how the model can be used for strategic decision making
In order to achieve these goals, data from Novartis Biologics, which focuses on large molecule
drug development, will be used to design and test the model.
1.4 Results
Through this thesis research at Novartis Biologics in Basel, Switzerland, a task-based Monte
Carlo simulation model was created to forecast drug development resource requirements. The
model forecasts the number of required headcount, measured in full time equivalents (iFTEs1),
and the manufacturing capacity, measured in the number of campaigns or manufacturing weeks.
The model was designed to be flexible and scalable using Microsoft Excel, coupled with Oracle
Crystal Ball software. The model is flexible in that tasks and new projects are easily assigned to
new functional groups or to new sites. The model is scalable in that new product types can be
added by copying the existing templates and modifying the tasks to represent that new product
type. The model structure described in this thesis could be used for any pharmaceutical
development process by changing the input variables and assumptions as appropriate.
When comparing the model projections against actual Novartis data, the model forecasts within
7% of the actual FTEs hired and estimates manufacturing capacity requirements within +/- three
manufacturing campaigns. The model forecasts the manufacturing utilization within 13% of the
currently accepted forecasting method. When compared with the overall industry data for large
molecule development, the model overestimates the actual number of launched products by up to
90%. This percentage suggests that even though the model closely estimates the Novartis
pipeline, the overall industry trends differ by company.
This thesis also demonstrates that the model is not only useful for forecasting future resources,
but also for evaluating different scenarios to make strategic decisions regarding resource or
capacity planning. The three case studies presented in this thesis are: a drug development
process improvement evaluation, an outsourcing evaluation, and an "at risk" development
evaluation.
This thesis meets the goals stated above and concludes with a number of recommendations.
First, a successful model depends on reliable data input. To ensure that the data are as accurate
1 Many companies measure human resources in terms of full time equivalents (FTEs). Typically, one FTE
represents the work performed by one full time equivalent employee working for 40 hours per week. This unit is
used to measure resources required for tasks, or asses the amount of resources available. If there is a task that
requires 20 hours per week every week, then that task requires 0.5 FTE. If a part-time employee works 30 hours per
week, then they are considered 0.75 FTE.
as possible, it is recommended to create a structured process that gathers model input on a
periodic basis and delivers forecast results to the appropriate stakeholders in a consistent and
timely fashion. Second, the model currently considers a standard set of assumptions for all
projects. However there is also more specific resource requirement information for the projects
that are currently in progress. By incorporating the specific information about current projects
and keeping the general information for future projects, the short term forecasting accuracy of
the model can be improved. Lastly, the model could be expanded for use in other areas of
Novartis or it could be used in more detail or granularity within Novartis Biologics. It will be
important to choose a specific application for the model and simplify the assumptions and
structure to best serve its overall objective.
1.5 Thesis Overview
This thesis is organized into six chapters. The first chapter (this chapter) provides an
introduction and an overview to the thesis and its contents. The second chapter summarizes the
drug development process, reasons for forecasting, and forecasting techniques. Chapter three
details the model framework, assumptions, and calculations. The fourth chapter evaluates this
model using three perspectives: (1) comparing model projections against historical project
pipeline data from the pharmaceutical industry, (2) comparing model projections against
historical Novartis headcount and manufacturing data, and (3) comparing model projections
against current manufacturing capacity planning methods. Chapter five demonstrates how this
model can be used to provide information for strategic decision making. The specific
evaluations are: a drug development process improvement evaluation, an outsourcing evaluation,
and an "at risk" development evaluation. Lastly, chapter six summarizes the key findings and
conclusions.
CHAPTER 2 - Background
This chapter outlines the drug development process, and provides reasons and common practices
for forecasting drug development resources.
2.1 Drug Development Process in the BioPharmaceutical Industry
Today there are two main types of pharmaceutical products: "small molecule" and "large
molecule" products. Small molecule products can be chemically synthesized and large molecule
products are grown in living cells that are genetically altered to produce the desired product
(Schuler, 2002). The large molecule products are also called "biologics." Since the
manufacturing equipment required for these two methods varies greatly, pharmaceutical
manufacturing capacity is divided to produce either one of these two products.
This thesis is supported by data collected at Novartis Biologics. The parent company, Novartis
AG, develops both new molecular entities (NME), which are new drugs under patent protections,
and generics, which are drugs off patent protection. Traditionally, generics have been small
molecule products; however, some of the first large molecule products have reached patent
expiration. This has launched the emergence of "biosimilars," which are the generic versions of
large molecule drug products. Novartis AG has launched the first two FDA and/or EU approved
biosimilars, Omnitrope@ and Binacrit@/Hexel@, under the brand name "Sandoz" (Novartis AG,
2010).
Novartis Biologics supports both NME and generic products. New molecular entity and generic
products are manufactured using one of two manufacturing methods, cell culture or microbial
fermentation. The four product and manufacturing combinations are:
e Cell culture - New molecular entities (NMEs) that are produced using mammalian cell
culture are classified as "cell culture" products. This is typically, but not limited to,
monoclonal antibodies.
" Microbial - NMEs that are produced using a microbial expression system such as E. coli
or yeast are classified as "microbial" products. This manufacturing method requires
different manufacturing steps and different equipment than cell culture products.
* Biosimilar cell culture - Generic version of a drug that is nearing patent expiration and is
produced using mammalian cell culture are classified as "biosimilar cell culture"
products.
* Biosimilar microbial - Generic version of a drug that is nearing patent expiration and is
produced using microbial expression systems are classified as "biosimilar microbial"
products.
Drug development covers starts when a new potential drug is discovered and continues until the
commercial launch of that product. Drug development organizations do not produce product for
sale, but rather product for testing to collect information regarding:
e Drug manufacturing requirements, such as Chemistry, Manufacturing and Controls
(CMC) information required by regulatory agencies like the FDA and EMEA
e Drug safety and efficacy data, supported through animal studies and clinical trials
" Drug stability data
In order to obtain this information, development groups must perform numerous small scale
manufacturing runs, develop analytical test methods, and execute those tests many times. Since
an organization produces information, the "demand" is the number of projects requiring
development and testing. In this way, it is the project that moves from group to group, while the
headcount resources and laboratory space are analogous to stationary manufacturing equipment
on an assembly line (Repenning, 2000). In this case, the "product" is either the information
generated by the functional groups or the clinical material that will eventually produce
information through clinical trial results. The overall development process for each product is
illustrated in Figures 1 and 2. The differences between NME and biosimilar development paths
are due to the different regulatory requirements.
" Early Process e Robust Product * Manufacture e Process * Manufacture * Preparations for * Process e Regulatory
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Figure 1 - New Molecular Entity (cell culture and microbial) Development Path
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Figure 2 - Biosimilar (biosimilar cell culture and biosimilar microbial) Development Path
Each drug typically takes seven to nine years to complete development (Parexel, 2009). Many
drug projects are terminated for a variety of reasons, which range from toxicological concerns to
poor clinical results, or even a saturated market with too much competition for it to launch. The
probability that a project will proceed in the drug development process is measured as the
"probability of success."
Different functional groups are needed during the various development stages. For instance,
formulation resources are required in the very beginning of product development, as well as the
very end when the product is launched and new dosage levels are requested. In contrast, the
drug product analytics are frequently tested and process analytical resources are required in all
eight steps.
In addition to needing specific resource types, different drug projects will require varying levels
of those resources. For instance, an "easy" drug candidate that can be manufactured using well
established manufacturing methods and evaluated with known test methods will require fewer
resources than a drug candidate with unusual manufacturing characteristics or undeveloped test
methods. Other factors that influence resource requirements include drug delivery methods,
number of formulations, and manufacturing yields.
Typically, large pharmaceutical companies like Novartis will have a number of projects in the
"pipeline," meaning that they are in various stages of development. Novartis Biologics is
experiencing significant growth as large molecule products are representing an increasing
portion of the overall Novartis pipeline (Novartis Annual Report, 2009). With the growing
pipeline, Novartis Biologics is evaluating headcount resource and manufacturing capacity
requirements to ensure quick and efficient drug development.
2.2 Forecasting Practices
Companies forecast because some decisions must be made years before the impact of that
decision is known. If a company chooses to expand manufacturing capacity it can take three to
five years to purchase land, design and construct facilities, and gain manufacturing approval
from regulatory agencies. Drug development requires employees with specific talent sets. The
recruiting, hiring, and training of these employees can take up to a year for some positions.
Additionally, office space and laboratory space can take two years to build and commission. For
these reasons, pharmaceutical companies commonly create strategic plans that outline expected
manufacturing, headcount and office space requirements for the upcoming five years. The
purpose of forecasting is to identify where resource or capacity gaps exist, and decide how to
address them.
There are a number of ways to forecast. Many times, management will request functional groups
to provide estimated resource requirements for a single predicted pipeline scenario, specifying
the number of projects expected in each development stage for upcoming years. Then, all
resource decisions are made based on that scenario. However, it is nearly impossible to predict
the exact scenario that will occur. Additionally, it can be very time consuming for management
to collect and assemble the data from many sources; and once the information is gathered, this
information is only relevant for a single scenario. If the main scenario or business strategy
changes, this manual forecasting process must be repeated. This process of manually collecting
the information unnecessarily wastes time.
Alternatively, modeling and simulation can also be used for forecasting. In modeling, one uses a
set of assumptions to calculate an expected outcome. Simulation involves varying those
assumptions in a way that represents the many possible scenarios that could occur. These
scenarios are tracked to understand the range of possible outcomes. Using modeling and
simulation for strategic planning began in the early 1970's when computers became a helpful
tool for rapid computing (Krueger, 1972). Healthcare companies have now started using
computer modeling for drug development and strategic capacity planning (Hynes, 2007 and
Heinzle, 2006). According to health care modeling expert James Stahl (Stahl, 2008), models and
simulations are used for one or more of the following reasons:
" To test something that is impossible to test through direct experimentation
e To better understand or predict the outcome of a complex system
* To aid in decision making
In this thesis, modeling is used for the second and third reasons. Drug development is very
complex with long timelines. Resource decisions must be made today in order to satisfy
requirements that will occur in one to three years.
To adequately staff development projects, pharmaceutical management teams can either
internally increase resources (headcount) or capacity (laboratory and office space, and
manufacturing), or outsource to a contract research organization (CRO) or contract
manufacturing organization (CMO). While outsourcing may be more expensive on a per man-
hour basis, it provides flexibility that capacity and headcount expansion cannot. Furthermore,
many industries face a long capacity expansion lead time. Therefore, capacity must be built
while products are in development, at a time when the success of each specific product is
uncertain. This could be a large reason for the steady increase of CRO and CMO involvement in
drug development and clinical manufacturing (Parexel, 2008). Alternatively, CMOs offer
efficiency in building capacity according to the overall industry needs. Rather than individually
building an overabundance of capacity, pharmaceutical companies can "share" this capacity risk
through CMO contracts. In a way, the pharmaceutical companies can use this as a hedging
strategy (Beckman, 2008). When deciding which activities to outsource, companies will
typically hire contract organizations to perform data-intensive projects and the company will
perform knowledge-intensive projects internally (Azoulay, 2004).
In order to make strategic decisions using the best information available, decision makers like to
know the forecasted headcount resources and manufacturing capacity requirements as well as the
variability of those requirements. This thesis develops a modeling tool to supply a better
understanding of the complex drug development system in order to assist in strategic decision-
making regarding future resources and capacity.
CHAPTER 3 - Methods and Tools
This chapter describes the model that forecasts resource requirements for drug development.
The model foundation was initially designed by Tamara Conant and is outlined in her thesis,
Modeling Variability for Biologics Strategic Planning (Conant, 2009). Conant created a model
to forecast FTE resources for Novartis Biologics. As part of this thesis research, the model was
modified by the current author to also forecast manufacturing capacity and allocate FTE resource
and manufacturing capacity requirements per site.
3.1 Problem Description
This model forecasts FTE and manufacturing capacity requirements for Novartis Biologics in
future years by answering the following two questions:
" Question A: How many projects are anticipated per development stage in future years?
" Question B: What level of FTE resources, manufacturing capacity, and financial
resources are required per site per year?
Novartis develops multiple product types, and each product has sequential development stages
(described in Chapter 2.1). Every development stage requires an average number of workdays
from different functional groups. Some functional groups are only located at one site, whereas
other functional groups are available at multiple sites and might specialize on certain product
types. Activities that are always performed at the same site are "fixed activities," while activities
that can be performed at multiple sites are "flexible activities." Some development stages
require manufacturing campaigns. The manufacturing sites available for these campaigns will
depend upon the product type and development stage. Each development stage takes an average
amount of time to complete; however, this number can vary depending on the product
complexity.
3.2 Model Assumptions and Input Data
The model is based on fixed and flexible assumptions. All user adjustable parameters are
flexible assumptions and can be changed according the user's information. Flexible assumptions
are listed below. The variable names are given for reference, and will be further defined later in
this section.
" Number of current projects (c,,d)
" Number of future projects (fy,,)
* Probability of success between development stages (Sp,d)
e Percent of projects performed at risk (Rp,d)
e Resources required per development stage and per functional group (FTES, MCp,,
MSp,,, for both fixed and flexible activities). See Appendix D for more information on
how this information is obtained.
" Site allocation of flexible activities that can be performed at multiple sites (x,,c,)
* Time required for each development stage (Td)
Fixed assumptions are inherent to the model design and cannot be changed without changing the
model structure. Fixed assumptions are listed here:
" All projects are represented by a "standard" project, requiring an average number of
resources (FTEs, manufacturing capacity, and financial resources).
e The resources required for a "standard" project this year are assumed to be the same
number of resources required for that type of project for the next ten years. No
organizational efficiency, productivity improvement, or technological advances are
factored into the model.
" All employees within the same functional group at any site are equally capable of
working on any type of project, and each employee can work on an unlimited fraction of
projects. Each FTE is only limited by the number of work days in the year.
* Manufacturing sites are interchangeable and campaigns are assigned per the site
allocation (x,,,), which is defined by the user.
* Activities in the next stage can only be started when all of the tasks in a previous stage
are completed.
e The progression of projects through the pipeline is fractional, not discrete. In other
words, if a project has a 50% chance of progressing from stage 4 to stage 5 (Sp,4 = 0.50),
and for one project in stage 4, the model will consider 0.50 projects progressing to stage
5.
e The model assumes risk neutrality and uses expected values. Fractional projects are
added. For example, four projects that all have a 50% chance of progressing are
considered two full projects.
" The organization is split into a finite number of groups and will remain that way for the
period of the forecast (model does not predict organizational structure changes).
* The model assumes that in each simulation run, a development stage takes the same
amount of time for all new molecular entity or biosimilar projects. For instance, if the
simulation generates a 1.5 year duration for development stage 4, then all projects will
take 1.5 years to complete stage 4 for all ten years of the forecast.
* Regardless of the phase duration time, the work required for that development stage is
spread evenly over the years required to complete the work.
* The model assumes that all future projects will start in development stage 1. This
assumption is not true for many in-licensed projects. Projects that are currently in-
licensed are included in the model by assigning the appropriate development stage to the
current project parameter, but all future projects are assumed to enter the pipeline at
development stage 1.
The assumptions listed above are important to understand when using the model for decision
making purposes. In the future, if any assumptions become inappropriate the model should be
adjusted according to the change required. Within Novartis, there are two individuals who serve
as the NME and biosimilar resource and capacity planning heads. These two individuals are the
model owners and are responsible for maintaining the model and communicating assumptions
and results to Novartis decision makers.
The data-oriented notation used in the model description is listed below. This information is
supplied by the model user. Individual variables are in italics, and matrices are in bold.
Cp,d = number of current (ongoing) projects of product type, p, in development
stage, d.
C = p x d matrix describing the current number of projects for each product type
in each development stage.
f, = number of future projects expected in year, y, for product type, p.
F = y x p matrix describing the number of projects expected for year, y. All new
projects that start each year are assumed to start at development stage 1.
Sp,d = probability of success for product type, p, at development stage, d.
Rp,d = fraction of projects performed at risk for product type, p, at development
stage, d.
Td = time required to complete development stage, d.
FTEPS = (g x d) matrix describing the number of FTEs required from each
functional group, g, to complete each development stage, d. There are multiple
matrices, one for each product type, p, requiring resources at site, s.
MCp,, = (g x d) matrix describing the number of manufacturing campaigns
required from each functional group, g, to complete each development stage, d.
There are multiple matrices, one for each product type, p, requiring resources at
site s.
MSp,, = (g x d) matrix describing the materials and services costs required from
each functional group, g, to complete each development stage, d. There are
multiple matrices, one for each product type, p, requiring resources at site, s.
FTEflexp,c = (g x d) matrix describing the number of FTEs required from each
functional group, g, to complete each development stage, d. This work is flexible
and can be performed at a number of the sites. There are multiple matrices, one
for each product type, p, requiring resources at center, c.
MCflexp,c = (g x d) matrix describing the number of manufacturing campaigns
required from each functional group, g, to complete each development stage, d.
These campaigns can be performed at a number of the sites. There are multiple
matrices, one for each product type, p, requiring resources at center, c.
MSflexp,5 = (g x d) matrix describing the materials and services costs required
from each functional group, g, to complete each development stage, d. These
costs are flexible and can be charged to a number of the sites. There are multiple
matrices, one for each product type, p, requiring resources at center, c.
xpIc's= fraction of flexible resources for product type, p, belonging to center, c,
that are performed at site, s.
3.3 Model Calculations
As mentioned in Section 3.1, the model addresses two main questions.
Question A: How many projects are anticipated per development stage in future years?
First, a forecast vector is calculated for each current project development stage Cp,d, determining
how many will proceed to the next development stage. A project will "graduate" to the next
development stage if it has a successful clinical trial outcome, or if it is developed at risk 2 . The
project forecast vectors are calculated as:
<Fc,,d> = <Cp,d, Cp,d[Sp,+Rp,1(1-Sp,1)], Cp,dSp,1 [Sp,2+Rp,2 (l-Sp, 2 )], Cp,dSp,lSp,2[Sp,3+Rp,3(1-Sp,3)], ... >
(Equation 1)
The matrix contains as many terms as the number of development stages (i.e. eight terms for
eight development stages). A separate forecast vector is calculated for each Cp,d. The term will
be 0 for all stages already completed and the probability of success Sp,d = 1 for all development
stages that have already passed (i.e. <Fe,,>= <0, 0, 0, 0, c,,5, c,,s[Sp, 5+Rp, 5(1-Sp, 5 )],
Cp,Sp,5 [Sp,6+Rp, 6(1-Sp,6)], csSp,Sp,6[Sp,7+Rp,7(1-Sp,7)]>)
A forecast vector is also calculated for each of the future projects, fy,. Similarly, this vector is
calculated as:
<Ffp> = <fy,p,fy,,[Sp,1+Rp,1(1-Sp,1)],fy,p Sp,i[Sp,2+Rp,2 (1-Sp,2)],fy,,Sp,1Sp,2[Sp,3+Rp,3(1-Sp,3)], ... >
(Equation 2)
Again, the vector contains as many terms as the number of development stages, and estimates the
number of projects that start in year, y, that will proceed into the next development stage.
Time matrices (T) allocate the work over future years. Multiplying the forecast vector by the
time matrix will allocate the resources into the appropriate year, y. Time matrix calculation is
2 Projects developed at risk will proceed to the next development step before the clinical trial outcome is known.
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described in detail in Appendix C. In general, the time matrix for current projects will be the
identity matrix if each development stage lasts exactly one year and there are no time delays.
The time matrix for future projects will be zeros until the year the future projects start; after that
year, the time matrix will be the identity matrix.
The total number of projects in each development stage, d, over the next y years is calculated by:
N, = <Fe>*T +<Ff>*T (Equation 3)
N, is a (d x y) matrix where d is development stage and y is the year. If each development stage
takes one year, and there are no time delays, the formulas to calculate each element of N, are
shown below, where each row represents the number of projects in that stage of development and
each column represents the number of projects in that year:
Y2
f2,pfi,,(Si + (1 - S,,)R,,)
c, 1 S1(S2 + (1 - S,,2)R,,2)
c,,7S7(S8 + (1 - S,,3)R,,3)
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f7,,(S1 + (1 - S,,)R,,)
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The N, matrix answers Question A, giving the number of projects expected per development
stage per year. This information is used to address Question B.
Question B: What level of FTE resources, manufacturing capacity, and financial resources
are required per site per year?
FTE Calculations
The model uses the N, matrix and the FTE resource assumptions to calculate the full time
equivalents (FTEs) required per site. The FTEs required at site, s, are:
FTES= N x FTES + p1 =1 xc (N, x FTE.flexpc) (Equation 5)
Equation 5 calculates a matrix (g x y) describing the number of FTEs required in each of the g
functional groups for each of the y years. The first term considers the fixed site activities always
performed at site, s. The project matrices N, are multiplied by the respective fixed site activity
matrix, FTEp,S, detailing the FTE support for project type, p, at site, s. Since there are multiple
product types, the matrices for all products (p=1 to p=P) are added together. Similarly, the
flexible site activity matrices are multiplied by the N, matrix for each product, and the site
allocation factor x,,c, is applied. Again, all of the flexible site activities for all product types are
added together for site, s. Adding the FTE requirements for fixed site activities and flexible site
activities gives the grand total of FTEs required at site, s, for each of the functional groups, g, in
upcoming years, y.
Manufacturing Campaign Calculations
Calculated in a similar fashion, the forecasted manufacturing campaigns are:
MCs= p1 N, x MC,, + Z,=1 c=1 xCs (N, x MC-flexp,c) (Equation 6)
This is a matrix (g x y) describing the number of manufacturing campaigns required in each of
the g functional groups for each of the y years. The project matrices N, are multiplied by the
respective fixed site manufacturing campaign matrix, MCp,s, specifying the manufacturing
campaigns required for project type, p, at site, s. Then the matrices for all products (p=1 to p=P)
are added together. Similarly, the flexible site manufacturing campaign matrices are multiplied
by the N, matrix for each product, and the site allocation factor xp,c,s is applied. Again, all of the
flexible site manufacturing campaigns for all product types are added together for site, s. Adding
the fixed site manufacturing campaigns and flexible site manufacturing campaigns gives the
manufacturing campaign grand total required at site, s, for each functional group, g, in upcoming
years, y.
Financial Calculations
The materials and services required are:
MSS = Z =1 N, X MSp,,5 + YP=1 Ef=1 x,,c, (N, x MS flex,,c) (Equation 7)
Equation 7 calculates a matrix (g x y) describing the total materials and services costs required in
each functional group, g, for each year, y. In the same way as the FTE and manufacturing
campaign calculations, the project matrices N, are multiplied by the respective fixed site
materials and services matrices, MSp'S, specifying the materials and service costs expected for
project type, p, at site, s. The matrices for all products (p=1 to p=P) are added together. Again,
the flexible site materials and services matrices are multiplied by the N, matrix for each product,
and the site allocation factor xp,cs is applied. Again, all of the flexible site materials and services
for all product types are added together for site, s. Adding the fixed site and flexible site
materials and services gives the grand total materials and services anticipated for site, s, for each
functional group, g, in upcoming years, y.
Additionally, one can calculate the total costs by considering FTEs, manufacturing campaigns,
and materials and services. To do this, some additional information is needed: <FTECOSTs>=
a vector (with g terms) listing the average cost per FTE in each of the g functional groups at site
s, MCWKS = average weeks per manufacturing campaign, and MCCOSTs = cost per week of
manufacturing time at site s. The overall site cost, <OSCs>, at site s is calculated using:
<OSCs> = FTEs*<FTECOSTs> + MCs*MCWKS*MCCOST + MS,
This <OSCs> vector (with y terms) describes the overall site costs for the next y years.

The model-oriented notation is summarized below. This information is calculated by the model.
Individual variables are in italics, vectors are contained in <brackets>, and matrices are in bold.
<FC,.d>= Forecast vector summarizing the number of Cp,d projects that will
graduate into the remaining development stages, d. The vector contains d terms,
one for each development stage.
<Ffp> = Forecast vector summarizing the number offy,, projects that will
graduate into the remaining development stages, d. The vector contains d terms,
one for each development stage.
T = Time matrix for each current project, Cp,d,, and future project, fy,, that
allocates the respective vector into the appropriate year. If there are no time
delays, and each development year takes one year, then T is an identity matrix. If
there are time delays and Td # 1, then T is calculated according to Appendix C.
N, = Number of projects expected per year, y, in development stage, d. There is
one (d x y) matrix for each product type, p.
FTES = Total FTEs forecasted for each functional group, g, needed at site, s, for
each year, y. There is one (g x y) matrix for each product type, p.
MC, = Total manufacturing campaigns forecasted for each functional group, g,
needed at site, s, for each year, y. There is one (g x y) matrix for each product
type, p.
MS, = Total materials and services forecasted for each functional group, g,
needed at site, s, for each year, y. There is one (g x y) matrix for each product
type, p.
<OSC> = Overall site costs for site, s, considering FTE, manufacturing
campaigns, and materials and service costs. This is a vector consisting of y
terms, forecasting the cost per year for the upcoming y years.
3.4 Novartis Model
The model designed for Novartis has seven product types (p = {cell culture 2-step, cell culture 3-
step, microbial, biosimilar cell culture, biosimilar microbial, vaccines, external}) and five
functional groups (g = {gA,gB,gC,gD,gE})- The model is usually used to project the next seven
years (y = {yo,y1,y2,y3,y4,y5,y6,y7}). Many of the model input variables listed in Section 3.2
carry a degree of uncertainty. In order to model this uncertainty, Crystal Ball Monte Carlo
simulation software is used to simulate the variability and test the sensitivity of the resource
forecasts. Crystal Ball, an Oracle software program, simulates many scenarios by populating
cells with randomly generated numbers according to probability distributions defined by the
user. The software runs many trials and records the outputs. This allows the user to observe the
variability of the model projections. See references for more information on Monte Carlo
simulation and the Crystal Ball software (Mun, 2006 and Charnes, 2007).
First, the user must define probability distributions for the future projects (fy,), development
stage duration (Td) and probabilities of success (Sp,d). For instance, the user can specify that the
time to complete development stage 1 has a BetaPERT probability distribution with a maximum
of 1.5 years and a minimum of 1.0 years. The user can then run the model for a set number of
simulations (1000 trials were used for this model) and determine the resource variation. Figure 3
shows the results of a simulation run involving 1000 trials and graphing the "high" and "low"
estimates. In this case the 10% percentile and 90% percentile outcomes are graphed; however,
that can be adjusted by the user.
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Figure 3 - Example of Model Output, FTE Forecast for functional group, gi.
Similar graphs are made for the manufacturing campaign and materials and services forecasts.
In summary, this model calculates the number of projects expected over the next seven years and
the resources required to support future projects. Through simulation, the model also projects
the potential variability of those resource needs. This information is useful for making long term
resource and capacity decisions.
CHAPTER 4 - Model Empirical Evaluation
This chapter uses three evaluations to demonstrate that the drug development process can be
described by a flexible and scalable model, and that the model produces reliable output. The first
part (Section 4.1) empirically evaluates the model's ability to forecast the correct number of
projects (N,). The second part (Section 4.2) empirically assesses the model's ability to forecast
resources required (FTEs, MCs). The third part (Section 4.3) empirically examines how similar
the model predictions are with a currently accepted Novartis model. The purpose of these
empirical evaluations is to compare the model to actual data and currently accepted practices.
4.1 Historical Pipeline Comparison
If the model is used with today's information, one would need to wait up to eight years to know
if the model is accurate. Alternatively, one can take data from the past, and run the model at a
certain point in history. The model projection can be compared against what actually happened
to assess the model accuracy.
This empirical assessment uses historical data, which are available for the biologics industry as a
whole to demonstrate how the model can be used to predict the number of projects each year
(N,), and how assumptions can be adjusted in order to best model the actual data. The following
graph summarizes a study performed by Pharmaprojects (Parexel, 2009).
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Figure 4 - Therapeutic mAbs in Development by Phase, 1995-2009
These data show the actual number of monoclonal antibodies in each development phase from
1995 to 2009. The square markers show the number of preclinical projects per year, the circles
show the number of Phase I projects, and so forth according the legend. In this empirical
evaluation, the 1995 data and the growth of the preclinical phase represent incoming projects.
The model is used to forecast the number of projects expected for the following seven years; and
this forecast is then compared to the number of projects that actually occurred during those years.
1995 Industry Comparison
Figure 5 summarizes the probabilities of success and phase duration assumptions. A 42%
probability of success between Phases I and II means that at the end of Phase I, 42% of the
projects will proceed to Phase II and 58% will be terminated.
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Figure 5 - Probability of Success and Phase Duration Assumptions for 1995 Industry
Comparison
The incoming projects are given by the number of precinical projects specified by the Parexel
data. Running the model with the assumptions above and comparing that information with the
actual data yields the results shown in Figures 6-9.
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Figure 6 - Phase I Model Forecast and Actual Number of Projects
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Figure 7 - Phase II Model Forecast and Actual Number of Projects
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Figure 8 - Phase III Model Forecast and Actual Number of Projects
Figure 9 - Launched Product Forecast and Actual Number of Projects
The model predicted the expected number of projects in Phase I within +/- 7 projects (or +/-
35%) for the 1995 forecast. This prediction is reasonably accurate for the purposes of long
range planning. However, the Phase II forecast was consistently lower than the actual number of
projects in Phase II. This trend is explored in detail below. The Phase III comparison estimates
the number of projects within +/- 7 projects (estimating high by up to 75% in 1998). Lastly, the
Launched Product comparison matches very nicely until after year 2000, where the actual data
flat-lines. There may have been an external factor involved during this period, as it appears to be
uncharacteristic considering the pipeline and past number of projects.
1995, 2000, and 2005 Industry Comparison
To test if the model consistently over or underestimates projects, and to see if these model
assumptions hold true over time, 2000 and 2005 were also evaluated in the same way as the 1995
case above. The percent difference was calculated between the model estimates and the actual
values, where percent difference = (model value - actual value)/actual value. So if the percent
difference is negative, the model underestimates the actual number of projects and if the percent
difference is positive then the model overestimates the actual number of projects. Figures 10-13
below show the evaluation results.
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Figure 10 - Phase I Comparison between Forecast and Actual (in Percent Difference) for 1995,
2000, and 2005.
The model estimated the Phase I projects reasonably well, within +/- 40%. There is no
overestimating or underestimating trend.
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The model consistently underestimates the number of projects in Phase IL Possible reasons for
this trend:
* The time duration for Phase II could be too low, and projects could actually be spending
more than two years in this phase.
e The probability of success between Phase I and Phase II could be lower than the model
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Figure 12 - Phase III Comparison between Forecast and Actual (in Percent Difference) for 1995,
2000, and 2005.
In all cases, the model overestimates the number of projects in Phase III, sometimes by as much
as 130%. Possible reasons for this trend:
" The Phase U1 time duration assumption could be too short, and the model could be
moving projects into Phase III prematurely.
" The probability of success from Phase II to Phase III used in the model could be too high,
or less than 75% of Phase II projects move into Phase IL.
" The model may be overestimating the Phase III duration time.
Figure 13 - Launched Product Comparison between Forecast and Actual (in Percent Difference)
for 1995, 2000, and 2005.
The model also tends to overestimate the number of launched products, in some cases by as
much as 60%. It is possible that the probability of success is actually too high in this case or that
projects are actually spending more time in previous phases and the model is running at an
accelerated pace.
To empirically assess the accuracy of the probability of success assumptions, the overall number
of projects predicted by the model is compared with the actual number of projects. Results are
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Figure 14 - Total Project Number Comparison between Forecast and Actual (in Percent
Difference) for 1995, 2000, and 2005.
It is interesting to note that even though the model tends to overestimate the number of projects
in Phases II, III and Launched products, the total number of projects is reasonably estimated by
the model. This suggests that the model is retaining a good number of projects, suggesting that
the phase durations are in need of adjustment, not the probabilities of success.
1995, 2000, and 2005 Industry Comparison with Adjusted Assumptions
According to an interview with a clinical trial coordinator, Phase II and Phase III duration can be
most variable. Phase III is typically a continuation of Phase II and the transition point between
the two phases can be somewhat arbitrary. Understanding this, the time for Phase II was
adjusted to four years and Phase III was reduced to two years. Figure 15 illustrates the new
model assumptions.
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Figure 15 - Adjusted Assumptions for Industry Comparison
Again, the percent difference between the model and actual data can be compared for the 1995,
2000, and 2005 forecasts. The results are shown in Figures 16-19. Since neither the probability
of success nor the phase duration of Phase I changed, the Phase I model forecasts did not change.
They are still represented in Figure 10.
Figure 16 - Phase II Comparison between Forecast with Adjusted Assumptions and Actual (in
Percent Difference) for 1995, 2000, and 2005.
The Phase II forecasts were much more accurate using the new assumptions; it appears that four
years in Phase II may better represent the actual case. The 1995 forecast was estimating about
50% low for four years out into the future, but that is still significantly better than in the initial











Figure 17 - Phase III Comparison between Forecast with Adjusted Assumptions and Actual (in
Percent Difference) for 1995, 2000, and 2005.
The Phase III comparison in this case is also more accurate than the first evaluation. Using the
original assumptions, the model was overestimating by as much as 130%; the model now
estimates within +/- 40%.
Figure 18 - Launched Product Comparison between Forecast with Adjusted Assumptions and
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The model continues to overestimate the numbers of launched products. It is possible that the
probability of success is too high at this step.
Total Number of Projects Comparison
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Figure 19 - Total Project Comparison between Forecast with Adjusted Assumptions
(in Percent Difference) for 1995, 2000, and 2005.
and Actual
Not surprisingly, the total number of products did not change significantly, only increasing
slightly due to the retention of projects in Phase II for an additional two years. The percent
difference seems reasonable, especially for the 2000 and 2005 forecasts.
Conclusions
As demonstrated by these empirical evaluations, the drug development process can be forecasted
using a flexible model. This chapter demonstrates that a model can be used to study historical
data, and assumptions can be adapted such that the model represents these data. After all
adjustments, this model predicts the number of cell culture projects in the pharmaceutical
industry within +/- 40%. This error is rather large for a number of reasons.
First, errors may reflect the fact that assumptions are based on data from many companies for
many different medical indications. Probabilities of success can depend on companies, and
phase duration can depend on medical indication. Aggressive companies with an appetite for
risk may push more products through clinical trials, while a conservative company that is risk
adverse or capital constrained may choose a limited number of products to move to clinical trials.
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It is possible that the industry is better at antibody design today than it was in 1995, so
probabilities of success may improve over time. Phase duration is dependent on drug indication.
A cancer drug may have an accelerated Phase I trial to treat terminal cancer patients quickly,
while, a hypertension drug may go through extended Phase I, Phase II and Phase III trials.
Therefore, there are many reasons as to why it is difficult to assign phase durations and
probabilities of success to represent a wide range of companies and drug indications.
Nevertheless, for the purpose of long range planning, general assumptions must be used to
describe a diverse pipeline of projects. It is impossible to know today the specific drug products
that will be successful, and the indications for which they will be used. However, if the project
pipeline is large enough, average values for probabilities of success and phase duration can be
helpful in determining resource needs. It is important that a company that uses a model like the
one described in this thesis also examines the phase duration and probabilities of success using
its own internal data as well, adjusting assumptions to best estimate the future pipeline as
demonstrated in this section.
4.2 Historical Resource Comparison
The purpose of this empirical exercise is to demonstrate that the model can provide reliable FTE
and manufacturing forecasts. FTE and manufacturing capacity information is held confidential
by pharmaceutical manufacturers. In this case, confidential Novartis data was used for this
evaluation, and the results are shown in terms of percent difference per year, nominal difference,
or percent capacity utilized, and does not reveal confidential information.
2007 FTE Comparison
Novartis has presentations from 2007, outlining the "current projects" at that point in time.
Using that information, the model can generate an FTE forecast beginning in 2007. The model
output can then be compared against the actual number of FTEs hired in 2007, 2008, and 2009.
The percent difference is calculated as percent difference = (model value - actual value)/actual
value. Figure 20 summarizes the results of the comparison, and shows that the model estimated
the actual number of total FTEs required within 7% for each year (2007, 2008, and 2009).




Figure 20 - 2007 Model Forecast comparison actual FTEs for 2007, 2008, and 2009, measured
in percent difference.
The model underestimated 2007 FTEs by 1%, underestimated the 2008 FTEs by 7%, and
overestimated the 2009 FTEs by 7%. These estimates are within acceptable error for long range
planning purposes, where +/- 10% can be considered good. If the model projects that 107 FTEs
are required and the actual number hired is 100 FTEs, then this margin of error is very
reasonable for long range planning purposes where an approximate estimate is more important
than precision.
Since the model also breaks down the resource requirements per functional group, model
forecast per group can be compared with the actual number of FTEs hired per group over a three










Figure 21 - 2007 Model Forecast comparison against actual FTEs per functional group for 2007,
2008, and 2009, measured in percent difference.
The model does not forecast the functional group FTEs as well as it forecasts the total FTEs.
Group D was overestimated by as much as 50% in 2007 and 2008. However, since this is the
smallest group in the department, this error was dwarfed by the overall total FTE approximation.
Additionally, the model consistently underestimates the Group C FTE requirements. This
encourages Novartis Biologics to re-evaluate the FTEs per project assumptions for Group C;
some tasks may be missing or have low work requirement estimates. The model approximates
within 20% of the actual required FTEs for Groups A, B and E for 2007, 2008, and 2009.
This exercise exposes a number of additional challenges regarding model forecasting. In the
period of these three years, the Novartis Biologics development organization has had a number
of reorganizations. The model is made to forecast the headcount needed for the current
organizational structure. However, when using the model for 2007, it was realized that some of
the functional groups did not exist in the same way that they do today. For the purpose of this
exercise, FTEs were classified into the appropriate bucket as the organization is structured today.
Even so, it is recognized that the organization will continue to change. It is not possible to
predict exactly how the organization will change. So it is most useful to model the current
organizational structure, understanding that the model must be updated as the organization
changes.
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This exercise also showed that future advancements that could change resource and capacity
utilization are not considered in the model. In 2007, there was only one type of product
development method, mAb 3-step. In recent years, another development method was
implemented, mAb 2-step. This will be discussed in further detail in Chapter 5.1. If this model
were used in 2007, it would have been difficult to predict that there would be over five types of
product development platforms in 2009. This is another fact that must be realized in using the
model: it only considers development platforms that are currently in use. If new types of
manufacturing methods or new types of products are discovered in the future, it is difficult to
predict these advancements using today's information.
Despite these shortcomings and "unknowns," resource forecasting remains a valuable exercise.
Even though the organizational structure or development platforms may change, decisions to
expand capacity, hire FTEs, or contract work must be considered and evaluated, using the best
information available.
2006 Manufacturing Campaign Comparison
A similar comparison is performed for the manufacturing capacity. Using Novartis 2006
presentations, the model is run as if the year were 2006. The numbers of manufacturing
campaigns per site are forecasted and compared to the actual number of cell culture
manufacturing campaigns. Novartis has two sites manufacturing Phase I/II clinical trial material,
and two sites manufacturing Phase III clinical trial material. The nominal difference is
calculated as (model value - actual value). The results are shown in Figures 22 and 23. A
positive number means that the model overestimated the number of campaigns by this amount,
and a negative number means that the model underestimated the number of campaigns by this
amount.
Figure 22 - Difference between model forecast and actual number of Phase I/II Cell Culture
Campaigns
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Figure 23 - Difference between model forecast and actual number of Phase III Cell Culture
Campaigns
As expected, the 2006 campaign predictions are within one campaign of the actual number of
campaigns. However, the model overestimates the Phase I/II cell culture campaigns by up to
three additional campaigns in 2008. Additionally, Site 1 Phase I/II campaigns seem to be
consistently overestimated by at least one campaign per year. For the purpose of long range
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planning, +/- three manufacturing campaigns is acceptable per Novartis management. However,
due to the Phase I/II trends, it would be worth investigating reasons for this overestimation. The
campaigns specified in the work packages may be either too frequent or in the incorrect
development stages. Since the Phase III estimates are close to the actual numbers of campaigns
performed, high probabilities of success in early stages are most likely not the reason for
manufacturing campaign overestimation.
Conclusion
When using historical Novartis data, the model forecasts FTE resource and manufacturing
capacity requirements reasonably. Any company using a model such as this one should perform
a similar assessment using actual internal data. As Novartis gains more experience in
biopharmaceutical development, this evaluation should be repeated to expose assumptions that
may need adjustment.
4.3 Current Capacity Forecasting Comparison
In 2007, the commercial manufacturing organization developed an independent modeling tool to
estimate manufacturing capacity requirements for commercial projects. In 2009, clinical trial
manufacturing data were added to the existing model. The commercial project model is on a
Microsoft Access database and extracts information from Microsoft Project files. If the
campaign dates for a project are known, they are entered into the Microsoft Project file; if the
campaign dates are unknown, the model uses a standard timeline for each project. Both the
"existing model" used by the commercial organization and the "new model" described in this
thesis use the same probabilities of success. Both models were used to forecast manufacturing
requirements for 2010-2018, only considering projects that start in 2010. The results are
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Comparison of Existing Model with New Model for Manufacturing Capacity
Forecasting
Both models use the same manufacturing timeline, so a close comparison is expected. The
average difference between the new model and the existing model is around 13%, with the
existing model usually estimating higher than the new model. This variation could be due to the
"time delay" factor that is used in the new model, and not used in the existing model. Fewer
manufacturing campaigns will be required as projects are pushed into the future by the delay. As
delays compound, the difference between these two models will increase over time. One can see
that the models are much closer in 2011 than 2018. Including delays are more realistic, and are
an acceptable difference according to the Novartis model owners.
Conclusion
This empirical evaluation is an enlightening way to examine how the model compares to
currently accepted practices. Figure 25 compares the two models in the evaluation. The
advantage of the new model is that it is faster to run, and includes tools to estimate development
headcount and financial requirements. The existing model is designed for commercial
manufacturing planning, and focuses on the commercial aspects of planning.
Can incorporate specific Yes No
project timelines?
Time to run a forecast? 45 minutes 3 minutes
Forecasting capabilities? Commercial Manufacturing Development Manufacturing
Development Manufacturing Development FTEs
Forecasting timeline? 8 years 8 years
Figure 25 - Commercial and Development Model Qualitative Comparison
Regardless of the modeling application, it is very useful to compare the new model with the
currently accepted best practice. This allows a better understanding of the new model's
capability and accuracy. The exercise also exposes opportunities to improve the new model if it
is lacking important capabilities.
I Simulation Capability? YesNO
CHAPTER 5 - Case Studies on Strategic Decision Evaluations
This chapter illustrates how a long term resource model is used to evaluate strategic decisions.
The impact on resources is evaluated for three potential evaluations: a drug development process
improvement evaluation, an outsourcing evaluation, and an "at risk" development evaluation.
5.1 Development Process Improvement Evaluation
The resource planning model is used to evaluate the impact of development process
improvements, when tasks are either added or removed, and estimate the effect on the number of
resources required. In this section, an actual example is presented and other possible uses for the
model are discussed.
Historically, Novartis Biologics has developed cell culture products using a three-step approach:
1. Platform Process - Develop cell line, master cell bank, and general process. Product from
this step is used for Preclinical studies and Phase I clinical trials.
2. Advanced Process - The general process is reviewed and revised to improve product titer
and yields. Product from this step is used for Phase II clinical trials.
3. Final Process - Lastly, the advanced process is adjusted and finalized for large scale
commercial manufacturing. Product from this step is used for Phase III clinical trials.
Every time the manufacturing process changes, there is potential that the product has also
changed due to different manufacturing conditions. Clinical trials begin using the platform
process product. After each process change, "comparability studies" must be performed to show
that the product is comparable to the product used in the ongoing clinical trials.
Ideally, there would be minimal process changes to reduce the number of comparability studies
and develop drugs more efficiently. Novartis Biologics has gained experience in drug
development, improving its knowledge base and ability to efficiently develop manufacturing
processes. Additionally, the process development group has been able to produce more efficient
cell lines, allowing for higher titers. With these advancements, Novartis Biologics is now able to
reduce cell culture development to a two-step process:
1. Platform/Advanced Process - Develop cell line, master cell bank, and manufacturing
process for development use. Product from this process is used for Preclinical studies,
and Phase I and Phase II clinical trials.
2. Final Process - Manufacturing process is finalized for large scale commercial
manufacturing. Product from this process is used for Phase III clinical trials.
This process improvement offers many resource savings by reducing the number of FTEs and
manufacturing campaigns required. The model developed through this thesis offers a method to
evaluate the resource savings.
As mentioned in Chapter 3.4, the model considers seven different product types for Novartis.
Two of those product types are cell culture two-step (p = cc2) and cell culture three-step (p =
cc3). As explained here, different resources are required for these two product types (FTEca,, #
FTEc,,) Figure 26 compares the two-step and three-step processes using the model
development framework.
Eight Development Stages as Defined in Model
Platform Process Advanced Process Final Process Traditional Three-Step Process
Platform/Advanced Final Process New Two-Step Process
Figure 26 - Three-step and Two-step development processes over the eight development stages.
The current 2010 project plan includes several newer projects that will be developed using the
two-step development approach. However, certain projects that started with three-step
development and are further along in the development stage must continue with the three-step
development strategy. Additionally, some projects are particularly challenging, or exhibit low
titers, and will require an additional development stage. For these reasons, the cell culture
projects in 2010 are a blend of two-step and three-step development projects. Using the model,
the resources required to execute the current cell culture projects were projected and compared to
the number of FTEs that would be required to run all cell culture projects with the two-step
method, or all cell culture projects with the three-step method. The results of this comparison are
shown in Figure 27. The actual FTEs have been removed, but percent differences are shown in
the dialog boxes.
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Figure 27 - Comparing FTEs Required for Two-Step and Three-Step Process Development
By using the two-step development for some of its products, Novartis Biologics is saving 0.6%
in FTE resources for 2010, showing that this is a more efficient development approach. In 2011,
two-step development enables 2.1% in FTE savings. Continuing to use the two-step
development as planned would offer a 5.0% FTE savings in 2018. If all cell culture products
could be developed using the 2-step method, there is potential for 7.0% FTE savings in 2018.
Since Novartis Biologics is expanding quickly, these FTE savings through more efficient drug
development practices are critical to success.
Conclusion
This evaluation demonstrates how potential business process improvements could be evaluated
using the resource model. Quality by Design (QbD) is another initiative within Novartis, as well
as within many other pharmaceutical companies. QbD recommends moving many quality
studies (requiring resources) earlier in process development. Since detailed quality testing
earlier means testing many projects that will eventually be terminated, QbD could potentially
require a greater number of resources. The impact on resources could be evaluated in a way
similar to the three-step vs. two-step development resource requirements evaluation.
5.2 Outsourcing Evaluation
Since Novartis Biologics has been growing quickly, it has not had the internal resources or
capacity available to complete all of the development tasks necessary. Novartis Biologics has
initiated outsourcing to prevent slowing down projects. In the past year, management has
developed an outsourcing strategy, and built close relationships with its primary outsourcing
partner. Novartis Biologics has found that supporting an outsourced project still requires some
level of internal resources from every functional group. This model is used to determine the
impact that outsourcing has on internal FTEs and manufacturing capacity requirements.
In the following example, the current outsourcing strategy is compared to three other strategies.
Figures 28 and 29 show the differences in FTEs and manufacturing campaigns using the
different outsourcing strategies. The "Current Strategy" represents the resource and capacity
forecasts if Novartis continued to use the current outsourcing levels. Option 1 represents
outsourcing one more project per year, Option 2 represents outsourcing two more projects per
year, and Option 3 represents outsourcing three more projects per year. In order to run this
analysis, all assumptions are fixed except for the classification of incoming projects. One of the
product types listed in Chapter 3.4 is "External" (p = ex); this means that the development work
is outsourced and performed externally. In this case, the resources required for external (or
outsourced) products at each site are FTEex,s and MCex,s, for FTEs and manufacturing campaigns,
respectively.
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Figure 29 - Clinical Campaign Manufacturing weeks for Various Outsourcing Strategies
In the different strategies, more projects were outsourced, and the number of "in-house" projects
was reduced according to the increase in outsourcing. Since the outsourcing strategy can only be
applied to projects going forward (i.e., projects currently started in-house cannot be outsourced),
there is less of an impact today and more of an impact in the future.
Conclusion
The information generated from this model is used to estimate the financial savings of reduced
internal resources vs. the additional cost of outsourcing. For instance, Option 1 reduces FTE
requirements by 5%-8% and manufacturing requirements by 6%-9%. If the cost savings of that
resource or capacity reduction is greater than the cost of outsourcing, this may be a good case to
support increasing the outsourcing strategy. Also, the forecast evaluation allows management to
examine manufacturing capacity requirements. When expanding, Novartis has the choice
between building more manufacturing capacity or outsourcing that capacity. This model offers
data to aid in that decision.
Clinical Campaign Manufacturing Weeks





5.3 At Risk Development Evaluation
Many pharmaceutical companies accelerate development activities to ensure there are no clinical
trial delays. For select products, management may choose to perform some activities before
clinical outcomes that normally trigger those activities are complete. These activities are
considered at risk, because development is proceeding at the risk of a negative clinical trial
outcome. If the product fails, these "at risk" activities are a waste. If the product succeeds, then
it can be advantageous to be ready with the next development step, which could help some
products reach the market more rapidly, thereby increasing the opportunity for market share
gain.
This case study demonstrates how the model can be used to examine the impact of at risk
development on the number of resources required. As defined in Chapter 3.2, the fraction of
projects performed at risk is represented by Rp,d. By changing Rp,d and holding all other
assumptions constant, resources required for various at risk strategies can be compared. The four
"at risk" strategies are shown in Figure 30. For instance, an aggressive at risk strategy is to
continue development of 80% of the projects waiting for milestone 1 results. This represents that
80% of projects waiting for milestone 1 results are continuing with further development "at
risk."






No at risk Modest Aggressive All at risk
0% 50% 80% 100%
0% 50% 80% 100%
0% 25% 20% 100%
0% 10% 10% 100%
Figure 30 - Assumptions for different "at risk" development strategies
Figure 31 shows the FTE requirements for the different development strategies defined in Figure
30. As the total number of projects increases in the future, the additional resources needed to
satisfy projects at risk increase as well. In 2010, performing all projects "at risk" increases the
FTE requirement by 10% over the "no at risk" strategy. In 2018, the resources necessary for an
"all at risk" strategy is 25% more than those needed for a "no at risk" strategy.
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Figure 31 - FTE Projections Considering Various At Risk Strategies
In practice, at risk decisions are made by analyzing each project individually. The cost of
proceeding at risk is compared to the potential advantages of the product reaching the market at a
faster speed. However, for long term forecasting, one cannot know which projects will be
successful and what markets the successful projects will serve. Therefore, it is impossible to
make individual "at risk" decisions today for projects well into the future. The purpose of this
model is to decouple the individual projects and make a general assumption for the future
(considering that the specific projects which will remain in the pipeline are uncertain). By
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Conclusion
This final case shows how adjustable assumptions are modified to assess the assumption
sensitivity. A similar evaluation could be performed to analyze the impact of the probabilities of
success assumptions.
The cases outlined in this chapter are only three examples of how this model can be used to aid
in strategic decision making. The impact of process improvements, outsourcing decisions, and
business risks can quickly be evaluated. If the model is maintained and updated according to
business practices, it can be used to evaluate future strategic decisions impacting FTEs and/or
manufacturing capacity.
CHAPTER 6 - Observations and Conclusions
This chapter summarizes the key observations and recommendations resulting from this thesis.
6.1 Key Observations
The key observations are divided into three sections. First the model evaluation results and
accuracy are presented. Second, many of the improvements and advantages that the model has
shown to date are discussed. Third, some of the potential challenges that may arise using the
model in the future are highlighted.
Model Evaluation Results
The model is able to forecast the number of future projects in clinical trials with 40% accuracy
when using industry-wide data. The forecast of the total number of launched projects was only
accurate within 90%. However, when considering Novartis Biologics internal data, the model
was able to predict the overall FTE requirements within 7% accuracy and FTEs by functional
group within 50% accuracy (this result is not materially significant because that functional group
is very small). The manufacturing campaigns per site are estimated within three campaigns.
When comparing currently accepted manufacturing projections for 2010 and beyond, the model
estimated within 13%. According to Novartis capacity planners, this degree of uncertainty is
acceptable for long range planning purposes and is an improvement over the previous forecasting
methods.
Model Advantages
This model delivered additional improvements to the forecasting and strategic planning
processes at Novartis. First, the model offers a platform to share common assumptions. Before
this model was developed and utilized, each functional group forecasted its own resource
requirements independently and project assumptions were not aligned. The model use now helps
to align assumptions across functional groups. Additionally, users can now perform sensitivity
analyses according to how assumptions may change and evaluate their impact without needing to
contact each functional group individually. Secondly, the model created a dialog among many of
the functional groups at multiple sites. Due to this model, some of these groups engaged in
conversations about workflow and tasks required for each development stage. This creates a
better understanding of the work required by each group, which can reduce rework and prevent
tasks from "slipping through the cracks." Thirdly, the model improves communication among
the upstream and downstream development groups within Novartis. There is a gradual transition
between development and commercial manufacturing, as many commercial sites will produce
the last clinical trial material in preparation for large scale manufacturing. With this model, the
commercial manufacturing groups also gain better insight into the number of incoming projects.
Lastly, the model helps Novartis Biologics plan capacity expansions strategically, deciding when
to outsource and when to expand their capacity. This provides a solid foundation to evaluate and
justify these decisions to upper level management within Novartis.
Potential Challenges
Although this model presents advantages, there are also many remaining limitations and
challenges to overcome. First, the model is very complex and can only be used by a trained set
of users (designated as the capacity planning heads). Because of this, each of the functional
groups must communicate more closely with these heads to make sure that all tasks and
requirements are sufficiently incorporated into the model. Then, as process changes occur, the
functional groups need to update the strategic heads rather than just updating their own
assumptions. The model needs accurate data to produce reliable results; this data may be
difficult to collect and update on a regular basis.
Secondly, due to the model's complexity, it is very easy to overlook assumptions that could
make a significant difference in the outcome. Currently, the capacity planning heads are very
aware of these assumptions, but if more people use the model, there is a danger in making
inappropriate assumptions. Additionally, the model is equipped with the capability of using
Crystal Ball software. However, this software is expensive (approximately $1,800 per user) and
requires a learning curve, which means that not everyone will have the access or the ability to
use that software.
Thirdly, the Novartis Biologics is undergoing many organizational changes. In some cases, it
could be either easy or difficult to accurately reflect those changes in the model. Lastly, capacity
expansions can be a highly political topic in a corporate environment. Even though the model
offers a legitimate basis to make expansion decisions, its complexity could lend itself to the
presumption that someone who understands the details has the control, and someone who is less
familiar with the details loses control. For this reason, a model must be presented transparently,
exposing all assumptions, for people to understand and believe in its results. The successful
implementation of this model will depend not only on data reliability, but also on transparency
and general acceptance.
6.2 Recommendations
For a model to be useful, it must contain accurate data, produce reliable results, and be accepted
by its users. A well defined process to ensure that data are collected from the correct sources and
updated periodically is important for obtaining accurate data. This process could involve an
annual data review. Following the review, the two model owners could generate a periodic
report to distribute to the appropriate stakeholders. The report should present the data that is
most helpful to key decision makers because understanding the concerns of these individuals will
give insight to more improvements. Close dialog among the model owners and upper
management/key decision makers may help gain support for and increase the usefulness of the
model.
Since it is impossible to predict the exact pipeline composition in the future, the model only
considers "average" resource requirements. In other words, each project is assumed to require
the same number of resources as other projects of the same product type. This is important for
future projects, where the resource requirements are not known. Interestingly, Novartis
Biologics uses another resource management program for short term resource management.
Technical project leaders input resource requirements for currently ongoing projects. If the
model can easily use information downloaded from the short term planning source, then this
could significantly help in estimating short term resources.
The model is able to run many scenarios using the Crystal Ball software, but the scenarios are
based on expected value calculations that reflect risk neutrality. Suppose that two projects have
a 50% probability of success and each project that succeeds requires 100 FTEs for development
support. According to the current design, the model will always expect an average of one project
to pass and one project to fail; this setup will always expect a requirement of 100 FTEs. If the
model were designed with discrete event simulation and a project was either "on" or "off', then
the output would show that 25% of the time no projects pass and 0 FTEs are required, 50% of the
time one project passes and 100 FTEs are required, and 25% of the time both projects pass and
200 FTEs are required. This gives greater insight to the possible variability of the outcomes, and
would be a better use of the Monte Carlo simulation capability. Even though the model gives an
accurate estimate of the expected value, the simulation does not represent the possible outcome
variations, providing another opportunity for future model improvement.
Finally, the model's complexity may become a hindrance to its expansion into other applications.
For instance, the model is currently being considered for expansion in two directions. It could be
expanded further for Novartis Biologics to include more detailed financial assumptions. Most
often, when making strategic decisions, the financial results play a significant role in that
decision, which means that this would be a very useful addition for Novartis Biologics. On the
other hand, Novartis as a whole is considering how to best use common manufacturing capacity
across divisions. A model such as this one could be an excellent tool for that application.
However, to be successful, the model would need to be less granular and specific and at the same
time, cover more product variety. It is difficult to create a "one model fits all" solution that
adequately balances the complexity that makes it accurate with the simplicity that makes it
broadly applicable. This could be an upcoming challenge for this model. The recommendation
is to choose a specific purpose and application for the model and craft the model such that it
satisfies that purpose.
6.3 Conclusions
This thesis demonstrates the following three points:
e The drug development process can be described by a flexible and scalable model.
" Reliable assumptions enable the model to provide reliable resource forecasts.
* The model can be used for strategic decisions such as process improvements,
outsourcing, and decisions to develop products at risk.
The first two points are supported by empirical evaluations of the model, described in Chapter 4.
All results were satisfactory to the model users and support the theory that the drug development
process can be modeled and accurately forecasted. The third point is supported by the case
studies in Chapter 5. The three cases examined are a very limited set of the possibilities for
which this model could be used for strategic decision making. Simulation modeling is a useful
resource planning tool, especially in areas of high uncertainty and variability.
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APPENDIX A: Glossary
CMC (Chemistry, Manufacturing, and Controls): Information a pharmaceutical company
must submit to the FDA to certify that the chemistry, manufacturing and controls are in
order to produce product of a consistent quality.
CMO (Contract Manufacturing Organization): Companies that perform drug development or
manufacturing on contract for a pharmaceutical company.
FDA (United States Food and Drug Administration): Agency that reviews and approves all
food and drug products that are sold in the United States.
FTE (Full Time Equivalent): This is the amount of work equal to one full time employee. For
example, two half time employees are considered one full time equivalent.
mAb (Monoclonal Antibody): Large molecule drug product that can be designed to interact
with or mimic the immune system. This is a biologic compound that is typically
produced in mammalian cell culture.
NME (New Molecular Entity): A compound or molecule that is patent protected.
APPENDIX B: Model Data Collection
Interviews were conducted with 33 Novartis employees from many functions including: process
and analytical development, project leadership, finance, management, capacity and operational
planning, portfolio management, manufacturing planners, and plant managers. Of the 33 people
interviewed, two individuals are the model owners.
Model development meetings were held with the two model owners once per month for six
months. The following bullets outline the timeline of the model design process:
e Month One: Understanding current state and project scope
The first meeting was used to discuss Tamara's original model and understand what the
stakeholders liked the best about it, and where the model needed improvement. Many
ideas were posed and prioritized on a list.
" Month Two: Present "mock-up" models to gain user feedback
At the second meeting, several "mock-ups," meaning examples of how the model could
look, were discussed. This approach afforded flexibility, since the mock-ups could be
modified quickly while talking with the key users.
* Month Three: Model test run
The first version of the new model was distributed a few days before the third meeting,
and the users were able to try using the model, and give further feedback to improve
usability. This approach was very helpful in identifying bugs or improper assumptions
within the model. By adjusting the inputs and reviewing the sensitivity of the outputs,
areas for additional data collection could be identified. After the third meeting, all of the
agreed upon changes were implemented into the final model, and the focus shifted onto
reliable data collection.
" Months Four and Five: Data collection
The fourth and fifth meetings focused entirely on collecting the correct data, updating
assumptions and identifying bugs and corrections within the model.
" Month Six: Model Evaluation
Preliminary results from the empirical evaluations (Chapter 4) were reviewed and
discussed.
APPENDIX C: Time Factor Matrix Calculation Detail
The standard logic for each cell (except the "Launched" row):
* There are two situations where project work is NOT performed (time factor = 0)
o All work for previous stages have not been completed
Excel code: IF SUM(years for all previous stages)>year, THEN time factor = 0
o All work for that stage was completed in previous years
Excel code: IF SUM(years for all previous stages + this stage)<year, THEN time
factor = 0
e There are two situations where project work IS performed (0 < time factor < 1)
o Stage is completed in that year
Excel code: IF both cases above are false
ANDIF SUM(years for all previous stages + this stage)>year, THEN time factor =
(1-all fractions of stage completed in previous years)
o Stage is worked on but not completed
Excel code: IF all cases above are false, THEN time factor = {(year-years or all
previous stages-fractions of stage performed in previous years*years for this
stage)/(years for this stage) }
The launched row will equal 1 if all of the development stages 1-8 are complete; otherwise, it
will equal 0.
Table Cl shows the matrix when the time in each phase is longer or shorter than expected, and
the logic programmed into a few cells are shown to demonstrate the logic.
Table C1 - Illustration of Time Factor Calculation
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Stage 1 Yrs
Project Time Dev. per
factor Stage S 1 2 4 5 6 7 8 9 10 11
CSP 1 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Preclinical 2 .5J 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Phl/PoC/PhIla 3 1 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0
Philb 4 1 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0
5 1 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0
PhIll 6 0.33 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0
7 0.33 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0
Submission 8 0.33 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0
Launched 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.0 1.0
For instance, cell F7 contains the following logic:
=IF(SUM(C6:C6)>F5;0;IF(SUM(C6:C7)<=E5;0;IF(SUM(C6:C7)<=F5;1-SUM(D7:E7);(F5-C6-
SUM(D7:E7)*C7)/C7)))
To break it down as described before:
=IF(SUM(C6:C6)>=F5;0; FALSE, stage is not waiting for previous stages
IF(SUM(C6:C7)<=E5;0; FALSE, stage is not already complete
IF(SUM(C6:C7)<=F5;1-SUM(D7:E7); FALSE, stage is not completed within the year
(F5-C6-SUM(D7:E7)*C7)/C7))) (3-2-0)/2 = 0.5 = 2012 Preclinical time factor
Similarly, cell 18 contains the following logic:
=IF(SUM(C6:C7)>15;0;IF(SUM(C6:C8)<=H5;0;IF(SUM(C6:C8)<=15;1-SUM(D8:H8);(15-
SUM(C6:C7)-SUM(D8:H8)*C8)/C8)))
Again, described in detail:
=IF(SUM(C6:C7)>=I5;0; FALSE, stage is not waiting for previous stages
IF(SUM(C6:C8)<=H5;0; TRUE, 0 = 2016 Phl/PoC/Phl time factor
IF(SUM(C6:C8)<=15;1-SUM(D8:H8);
(I5-SUM(C6:C7)-SUM(D8:H8)*C8)/C8)))
This time factor matrix is slightly different for projects that start in the future versus projects that
have already started. For projects that start in the future, the time factors for each year prior to
the start will be zero. For projects that have already started, the current stages do not depend on
the length of the previous stages that have already been completed (all completed stages will
have a required time of zero).
APPENDIX D: Work Package Calculation Detail
The resources required per product per development stage are determined through a compilation
of data from many sources. Each functional group provides a list of tasks that they perform, and
a specified number of workdays for each task for each development stage. All of the tasks are
compiled to create a work package for each drug product. These work packages define all of the
development tasks required for the eight stages of development, along with the number of FTEs,
manufacturing campaigns and materials and services costs required. Table Dl shows an
example of the work package input and some of the resulting FTE, MC (manufacturing
campaign) and MS (materials and services) matrices.
Work package task input section (top), fixed site activities matrices for Site 1
middle), and flexible site activity matrices for Launch Site (bottom)
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In the top input section, the user identifies the tasks and resources required along the eight
development stages (S 1-S8), and assigns each task to a functional group and site. For the
purpose of this demonstration, the Functional Groups A, B, C, and D and Sites 1 and 2 are used.
The site assignment can be either a fixed site that always performs that task for all projects of
that type, or the site assignment can be flexible if multiple sites have the ability to perform that
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flexible site activities are classified as activities that occur at the Competence Center (CC),
Development Site (DS) or Launch Site (LS).
The fixed site activities will always be allocated to the site responsible for that activity.
However, the flexible site activities are assigned based on a site allocation factor, xp,c,s, where
p=product type, c=center, and s=site. Table D2 shows an example of the flexible activity site
allocation factors which are defined by the user.
Table D2 - Example of Flexible Activity Site Allocation Factors
Flexible Activities Site Allocation Site 1 Site 2
Cell Culture CC 1 0
Cell Culture DS 0.5 0.5
Cell Culture LS 0 1
Microbial CC 1 0
Microbial DS 0.5 0.5
Microbial LS 0 1
Biosimilar Cell Culture CC 1 0
Biosimilar Cell Culture DS 0.5 0.5
Biosimilar Cell Culture LS 0.25 0.75
Biosimilar Microbial CC 0 1
Biosimilar Microbial DS 0.25 0.75
Biosimilar Microbial LS 1 0
For instance, 100% of the cell culture competence center work is performed at Site 1 (xc,cc,1 =
1), while 50% of the cell culture development site work is performed at Site 1 and the other 50%
is performed at Site 2 (xcc,DS,1 = Xcc,DS,2= 0.5).
